Journals / ANKEM Dergisi / 2013 / Cilt: 27 - Sayı: 4

Investigation of triple synergistic activities of the novel cationic steroid antibiotic csa-13, with colistin and various antibiotics against pseudomonas aeruginosa strains ısolated from cystic fibrosis patients

Katyonik steroid antibiyotik csa-13’ün, kolistin ve çeşitli antibiyotiklerle kombinasyonlarının kistik fibrozlu hastalardan izole edilen pseudomonas aerugınosa suşlarına karşı üçlü sinerjistik etkileri

Pages
196–205
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We showed that triple combination of CSA-13, a new cationic steroid molecule derived from cholic acid offers new perspectives as a new treatment option for P.aeruginosa infections in CF patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, in vitro double and triple synergistic activities of the novel cationic steroid antibiotic CSA-13, with colistin, tobramycin and ciprofloxacin were assessed against Pseudomonas aeruginosa strains isolated from cystic fibrosis (CF) patients.
📊
Key Findings & Data:Combinations of CSA- 13 plus colistin, together with tobramycin and ciprofloxacin were measured using checkerboard and the time-kill curve (TKC) method.
💡
Conclusion & Impact:We showed that triple combination of CSA-13, a new cationic steroid molecule derived from cholic acid offers new perspectives as a new treatment option for P.aeruginosa infections in CF patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, in vitro double and triple synergistic activities of the novel cationic steroid antibiotic CSA-13, with colistin, tobramycin and ciprofloxacin were assessed against Pseudomonas aeruginosa strains isolated from cystic fibrosis (CF) patients. MICs and MBCs were determined by microdilution technique according to CLSI guidelines. Combinations of CSA- 13 plus colistin, together with tobramycin and ciprofloxacin were measured using checkerboard and the time-kill curve (TKC) method. Susceptibility testing demonstrated that the MICs were ranging 0.5-2 μg/ml. The MBCs were equal to or two-fold greater than those of the MICs. According to the double combination studies using the microdilution checkerboard method, synergistic interactions were most frequent with CSA-13-colistin combination. The results of TKC analysis demonstrated rapid bactericidal activity of CSA-13. Combination TKC analysis demonstrated additive effect with colistin plus tobramycin and colistin plus ciprofloxacin. The addition of CSA-13 as a third antibiotic to these combinations, led to a synergistic effect. We showed that triple combination of CSA-13, a new cationic steroid molecule derived from cholic acid offers new perspectives as a new treatment option for P.aeruginosa infections in CF patients

Özet

Bu çalışmada, yeni bir katyonik steroid antibiyotik olan CSA-13’ün kolistin ve çeşitli antibiyotiklerle kombinasyon halinde kistik fibrozlu hastalardan izole edilen Pseudomonas aeruginosa suşlarına karşı oluşturduğu ikili ve üçlü sinerjistik etkisi araştırılmıştır. MİK ve MBK değerleri, CLSI’nın önerdiği mikrodilüsyon tekniği ile saptanmıştır. Antibiyotiklerin ikili ve üçlü kombinasyonlarının etkileri mikrodilüsyon “checkerboard” ve zamana bağlı öldürme yöntemleri kullanılarak ölçül- müştür. Antibiyotiklerin MİK değerleri 0.5-2 μg/ml arasında değişmektedir. MBK değerleri ise MİK değerlerine eşit yada iki katı değerindedir. Mikrodilüsyon “checkerboard” tekniği kullanılarak yapılan ikili kombinasyon çalışmalarında en fazla siner- jistik etki CSA-13-kolistin kombinasyonu ile elde edilmiştir. Zamana bağlı öldürme deneylerinin sonuçlarına göre CSA-13, hızlı bir bakterisidal etki göstermiştir. Zamana bağlı öldürme yöntemine göre kolistinin tobramisin ve siprofloksasin ile olan ikili kombinasyonlarının aditif etkili olduğu saptanmıştır. Bu ikili kombinasyonlara CSA-13’ün üçüncü antibiyotik olarak eklenmesi ile sinerjistik etki ortaya çıkmıştır. Sonuç olarak, kolik asitten türemiş olan yeni bir katyonik steroid yapıda molekül olan CSA-13’ün de içinde bulunduğu bu üçlü kombinasyonların, kistik fibrozlu hastalardaki P.aeruginosa infeksiyonlarının tedavisine yeni bir bakış açısı kazandıracağı düşüncesindeyiz.

🔖

Cite This Article

GÜZEL, Ç. B., ERTURAN, Z., SAVAGE, P. B., GERÇEKER, A. A. (2013). Investigation of triple synergistic activities of the novel cationic steroid antibiotic csa-13, with colistin and various antibiotics against pseudomonas aeruginosa strains ısolated from cystic fibrosis patients. ANKEM Dergisi, Cilt: 27 - Sayı: 4, 196–205. https://ajindex.com/articles/152255

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Arda B. Dirençli non-fermantatif Gram negatif bakteri infeksiyonlarının tedavi ve yönetimi, ANKEM Derg 2011;25(Ek 2):45-9
  2. Bozkurt-Guzel C, Gerceker AA. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudo- monas aeruginosa strains isolated from cystic fib- rosis patients, Chemotherapy 2008;54(2): 147-51. http://dx.doi.org/10.1159/000119741 PMid:18322363 3. Bozkurt-Guzel C, Savage PB, Gerceker AA. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin and ciprofloxacin against Pseudomonas aerugino- sa strains isolated from cystic fibrosis patients, Chemotherapy 2011;57(6):505-10. http://dx.doi.org/10.1159/000335588 PMid:22286090 4. Bucki R, Sostarecz AG, Byfield FJ, Savage PB, Janmey PA. Resistance of the antibacterial agent ceragenin CSA-13 to in activation by DNA or F-actin and its activity in cystic fibrosis sputum, J Antimicrob Chemother 2007;60(3):535-45. http://dx.doi.org/10.1093/jac/dkm218 PMid:17584802 5. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel cerage- nin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug- resistant P.aeruginosa, J Antimicrob Chemother 2008;61(2):365-70. http://dx.doi.org/10.1093/jac/dkm457 PMid:18079128 6. Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activities of ceragenins against cli- nical isolates of resistant Staphylococcus aureus, Antimicrob Agents Chemother 2007;51(4):1268-73. http://dx.doi.org/10.1128/AAC.01325-06 PMid:17210765 PMCid:PMC1855519 7. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial sus- ceptibility tests for bacteria that grow aerobically: Seventh Edition: Approved Standard M7-A7, Wayne, PA, USA, (2006)
  3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. M100-S20, Wayne, PA, USA, (2010)
  4. Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis: report of the UK Cystic Fibrosis Trust antibiotic working group, 3. baskı, Cystic Fibrosis Trust, Kent (2009)
  5. Epand RF, Pollard JE, Wright JO, Savage PB, Epand RM. Depolarization, bacterial membrane composition, and the antimicrobial action of cera- genins, Antimicrob Agents Chemother 2010;54(9):3708-13. http://dx.doi.org/10.1128/AAC.00380-10 PMid:20585129 PMCid:PMC2934994 11. Falagas M